


STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN TASOCITINIB CITRATE
 PRONUNCIATION tas" oh si' ti nib
 THERAPEUTIC CLAIM Treatment of immunological disorders

CHEMICAL NAMES

- 1-Piperidine-4-carbonitrile, 4-methyl-3-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-β-oxo-, (3R,4R)-4-methyl-1,3-propanedicarboxylate (1:1)
- 3-((3R,4R)-4-methyl-1-methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxo-propane nitrile-2-hydroxypropane-1,2,3-tricarboxylate (1:1)

STRUCTURAL FORMULA



MOLECULAR FORMULA $C_{16}H_{20}N_6O \cdot C_6H_8O_7$
 MOLECULAR WEIGHT 504.5
 TRADEMARK None as yet
 MANUFACTURER Pfizer, Inc.
 CODE DESIGNATION CP-690, 550-10
 CAS REGISTRY NUMBER 540737-29-9

Note: The adopted name *tasocitinib citrate* (N10/M37) has been rescinded and replaced by adopted name *tofacitinib citrate*. Please see the adoption statement for *tofacitinib citrate*.